Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis

doi:10.5313/wja.v3.i2.181

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 2

This Article

(404)

(387)

(0)

(13408)

(2)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Anesthesiology

ISSN

2218-6182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Original Article

World J Anesthesiol. Jul 27, 2014; 3(2): 181-188
Published online Jul 27, 2014. doi: 10.5313/wja.v3.i2.181

Table 5 Univariate comparison results: VAS_pain and VAS_impact

	VASpain	VASimpact
	RR	RR
Group	8.7270	3.4270
Day	0.5036	0.5065
Group × day	0.1513	0.1918

Univariate comparison results are presented on data from study participants completing the study. No significant findings were noted between comparisons. RR: Relative risk.

Full Size Table

Citation: Turcotte DA, Doupe M, Torabi M, Gomori AJ, Ethans K, Esfahani F, Galloway K, Namaka MP. Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis. World J Anesthesiol 2014; 3(2): 181-188
URL: https://www.wjgnet.com/2218-6182/full/v3/i2/181.htm
DOI: https://dx.doi.org/10.5313/wja.v3.i2.181

Turcotte DA, Doupe M, Torabi M, Gomori AJ, Ethans K, Esfahani F, Galloway K, Namaka MP. Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis. World J Anesthesiol 2014; 3(2): 181-188 [DOI: 10.5313/wja.v3.i2.181]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.